Evidence map›Paper›PMID 42438311›Full record

ArticleBritish journal of haematology2026

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

Catherine Gutierrez Moore, Donian I Chyong, Naval Daver, Brandon J Aubrey, Kayleigh R Marx, Koichi Takahashi, Yasmin Abaza, Catherine C Smith, Philip C Amrein, Hanno Hock and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Catherine Gutierrez MooreMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-7453-2577
Donian I ChyongMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Naval DaverMD Anderson Cancer Center, Houston, Texas, USA.
Brandon J AubreyMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Kayleigh R MarxMD Anderson Cancer Center, Houston, Texas, USA.
Koichi TakahashiMD Anderson Cancer Center, Houston, Texas, USA.
Yasmin AbazaRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
Catherine C SmithUniversity of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0160-7026
Philip C AmreinMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Hanno HockMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Gabriela HobbsMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Rupa NarayanMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-7104-1163
Michelle H LeeMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Jenna A MoranMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Meghan BergeronMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Julia E FosterMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Alexander E PerlUniversity of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-1463-2231
Mark J LevisJohns Hopkins Cancer Center, Baltimore, Maryland, USA.
Courtney D DiNardoMD Anderson Cancer Center, Houston, Texas, USA.
Andrew M BrunnerMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Amir T FathiMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Funding

National Institutes of Health, USA T32 Ruth L. Kirschstein Institutional National Research Service
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acute myeloid leukaemiaenasidenibFLT3gilteritinibIDH1IDH2ivosidenibmidostaurinquizartinib

Identifiers

PMID42438311
PMCPMC13570131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.